European Union - English - EMA (European Medicines Agency)

sanofi pasteur - influenza a virus subtype h1n1 haemagglutinin, recombinant, influenza a virus subtype h3n2 haemagglutinin, recombinant, influenza b virus victoria lineage haemagglutinin, recombinant, influenza b virus yamagata lineage haemagglutinin, recombinant - influenza, human - vaccines - supemtek is indicated for active immunization for the prevention of influenza disease in adults.supemtek should be used in accordance with official recommendations.

Malta - English - Medicines Authority

sanofi pasteur 14 espace henry vallée , 69007 lyon, france - influenza vaccine, split virion, inactivated - suspension for injection in pre-filled syringe - influenza vaccine (split virion, inactivated) a/victoria/4897/2022 (h1n1) pdm09 - like strain (a/victoria/4897/2022 ivr-238 15 µg a/darwin/9/2021 (h3n2) - like strain (a/darwin/6/2021, ivr-227 15 µg b/austria/1359417/2021 - like strain (b/austria/1359417/2021 bvr-26 15 µg b/phuket/3073/2013 - like strain (b/phuket/3073/2013, wild type) - vaccines

Australia - English - Department of Health (Therapeutic Goods Administration)

seqirus pty ltd - influenza virus haemagglutinin, quantity: 15 microgram - injection, suspension - excipient ingredients: water for injections; sodium chloride; monobasic potassium phosphate; dibasic sodium phosphate dihydrate; magnesium chloride hexahydrate; potassium chloride - for the prevention of influenza caused by influenza virus, types a and b contained in the vaccine. the vaccine is indicated for use in adults and children 6 months of age and older. for full details regarding recommendations for influenza vaccination, please refer to the relevant national immunisation guidelines.

Australia - English - Department of Health (Therapeutic Goods Administration)

seqirus pty ltd - influenza virus haemagglutinin, quantity: 15 microgram - injection, suspension - excipient ingredients: water for injections; sodium chloride; monobasic potassium phosphate; dibasic sodium phosphate dihydrate; magnesium chloride hexahydrate; potassium chloride - for the prevention of influenza caused by influenza virus, types a and b contained in the vaccine. the vaccine is indicated for use in adults and children 6 months of age and older. for full details regarding recommendations for influenza vaccination, please refer to the relevant national immunisation guidelines.

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

split virion, inactivated) suspension for injection 0.5ml pre-filled syringes (sanofi - influenza virus split virion - suspension for injection

Australia - English - Department of Health (Therapeutic Goods Administration)

seqirus pty ltd - influenza virus haemagglutinin, quantity: 15 microgram - injection, suspension - excipient ingredients: monobasic potassium phosphate; magnesium chloride hexahydrate; sorbitan trioleate; squalene; sodium citrate dihydrate; citric acid monohydrate; calcium chloride dihydrate; potassium chloride; water for injections; sodium chloride; dibasic sodium phosphate dihydrate; polysorbate 80 - active immunisation against influenza in persons 65 years of age and older.

Australia - English - Department of Health (Therapeutic Goods Administration)

seqirus pty ltd - influenza virus haemagglutinin, quantity: 15 microgram - injection, suspension - excipient ingredients: monobasic potassium phosphate; magnesium chloride hexahydrate; sorbitan trioleate; squalene; sodium citrate dihydrate; citric acid monohydrate; calcium chloride dihydrate; potassium chloride; water for injections; sodium chloride; dibasic sodium phosphate dihydrate; polysorbate 80 - active immunisation against influenza in persons 65 years of age and older.

Ireland - English - HPRA (Health Products Regulatory Authority)

sanofi pasteur - a/victoria/4897/2022 (h1n1)pdm09-like strain (a/victoria/4897/2022, ivr-238; a/darwin/9/2021 (h3n2) - like strain (a/darwin/9/2021, ivr-228); b/austria/1359417/2021 - like strain (b/michigan/01/2021, wild type); b/phuket/3073/2013 -like strain (b/phuket/3073/2013, wild type) - suspension for injection in pre-filled syringe - 15 microgram(s) - influenza vaccines; influenza, inactivated, split virus or surface antigen

Australia - English - Department of Health (Therapeutic Goods Administration)

glaxosmithkline australia pty ltd - influenza virus haemagglutinin, quantity: 15 microgram - injection, suspension - excipient ingredients: dl-alpha-tocopheryl acid succinate; potassium chloride; sodium chloride; water for injections; polysorbate 80; dibasic sodium phosphate dodecahydrate; magnesium chloride hexahydrate; octoxinol 10; monobasic potassium phosphate - fluarix tetra is a quadrivalent vaccine indicated for active immunisation of adults and children from 6 months of age for the prevention of influenza disease caused by the influenza virus types a and b contained in the vaccine (see section 5.1 pharmacodynamic properties, clinical trials).,the use of fluarix tetra should be based on official recommendations.

Australia - English - Department of Health (Therapeutic Goods Administration)

glaxosmithkline australia pty ltd - influenza virus haemagglutinin, quantity: 15 microgram - injection, suspension - excipient ingredients: dl-alpha-tocopheryl acid succinate; potassium chloride; sodium chloride; water for injections; polysorbate 80; dibasic sodium phosphate dodecahydrate; magnesium chloride hexahydrate; octoxinol 10; monobasic potassium phosphate - fluarix tetra is a quadrivalent vaccine indicated for active immunisation of adults and children from 6 months of age for the prevention of influenza disease caused by the influenza virus types a and b contained in the vaccine (see section 5.1 pharmacodynamic properties, clinical trials).,the use of fluarix tetra should be based on official recommendations.